Pershing Square Lotus Award for Ovarian Cancer Research
The Pershing Square Lotus Award for Ovarian Cancer Research supports cancer researchers pursuing bold, high-risk ideas to improve understanding, diagnosis, prevention, or treatment of ovarian cancer.
Browse similar grants
Funder: Pershing Square Philanthropies
Due Dates: January 4, 2027 (Applications open) | February 1, 2027, 5:00 p.m. ET (LOI deadline)
Funding Amounts: $750,000 over three years ($250,000 per year, including indirect costs)
Summary: Supports bold, high-risk, high-reward ovarian cancer research and work in other cancers with potential impact on ovarian cancer.
Key Information: Lead PIs without demonstrated ovarian cancer experience must include a collaborator with an ovarian cancer background.
Description
The Pershing Square Foundation’s Lotus Award combines its priorities in women’s health and cancer by supporting innovative research on ovarian cancer, an understudied and underfunded disease with limited early-detection and treatment options. The program seeks both established ovarian cancer researchers pursuing their boldest ideas and investigators bringing relevant expertise from other cancer fields.
Supported work may include basic research, early detection, vaccines and cell therapies, realistic disease models, novel technologies, dormant-cell research, and translational or therapeutic applications. The award emphasizes ideas that may be too risky for traditional funding but could produce transformative findings. Priority goes to bold projects aimed at curing the disease, with clearly defined potential to improve understanding, diagnosis, prevention, or treatment of primary or recurrent ovarian cancer.
